Aurinia Pharmaceuticals Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; financial amounts are in U.S. dollars. Aurinia commercializes LUPKYNIS (voclosporin) for adult patients with active lupus nephritis and is developing AUR200 and AUR300.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparator |
|---|---|---|
| Revenue | $34.4 million | $21.6 million |
| Product revenue | $34.3 million | $21.5 million |
| Operating expenses, including cost of sales and other expense | $64.0 million | $59.5 million |
| Operating loss | $29.6 million | $37.9 million |
| Interest income | $3.8 million | $0.3 million |
| Net loss | $26.2 million | $37.6 million |
| Basic and diluted loss per share | $0.18 | $0.27 |
| Net cash used in operating activities | $31.7 million | $46.7 million |
- Management reported gross margin of approximately 99% in both periods.
- At March 31, 2023, cash, cash equivalents, restricted cash and short-term investments totaled $361.5 million, down from $389.4 million at December 31, 2022. Working capital was $381.6 million, versus $396.4 million at year-end.
- Total liabilities were $61.4 million and shareholders’ equity was $390.4 million. The filing does not report conventional financial debt; liabilities chiefly include accounts payable, accrued and deferred compensation, and operating leases.
Changes and operating developments
- Revenue increased 59% year over year, primarily due to greater LUPKYNIS market penetration. Aurinia reported 1,731 patients on therapy at quarter-end, compared with 1,071 a year earlier; patient start forms were 466 versus 461.
- SG&A increased $4.9 million to $50.1 million, mainly from professional services, share-based compensation, and travel-related costs. R&D rose $0.5 million to $13.2 million: higher employee and share-based compensation was partly offset by lower CRO costs after completion of the AURORA 2 continuation study.
- Operating cash use declined by $15.1 million year over year, principally reflecting increased cash receipts from LUPKYNIS sales. Interest income rose with higher investment yields.
- U.S. sales concentration remains high: two customers represented approximately 99% of revenue in both periods and 99% of net trade receivables at March 31, 2023.
Outlook, risks and unusual items
- Runway: Management believes available cash and investments are sufficient to fund current plans for at least the next few years. No specific revenue, profit, or cash-flow guidance is provided.
- Pipeline and commercial progress: AUR200 was projected to have an IND submission in 2023 and AUR300 in 2024. LUPKYNIS received Swiss regulatory approval on April 24, 2023; the filing also describes an April 2023 renal-biopsy sub-study result and a newly issued U.S. method-of-use patent that Aurinia intends to list in the Orange Book.
- Manufacturing lease: Following operational qualification of the Lonza monoplant in April 2023, Aurinia expected to recognize an approximately $111 million right-of-use asset and $88 million lease liability. These amounts were not included in the March 31 balance sheet and reflect a significant subsequent-period commitment.
- Key risks: Revenue depends heavily on two U.S. customers and may fluctuate with their ordering and inventory levels. Patient-start and on-therapy metrics do not directly predict revenue; conversion, persistence, access, dosing, and discontinuations are uncertain. The company also cites supply-chain, inflation, interest-rate, foreign-currency, credit, and geopolitical risks, including the Ukraine conflict and related sanctions.
- The company reported no material change to its previously disclosed risk factors, no material legal-proceeding developments, and no material change in disclosure controls; management concluded disclosure controls were effective.
Important facts for investors to verify
- Whether LUPKYNIS sales growth and patient persistence translate into sustained revenue, given customer concentration and inventory/order timing.
- Progress and timing of AUR200 and AUR300 development and their projected IND submissions.
- Actual financial-statement recognition and ongoing costs of the Lonza monoplant lease, plus commercial supply needs.
- Cash burn, investment income, and whether management’s stated multi-year runway remains supported by operating results and commitments.
- Regulatory and commercial progress in Otsuka territories, including the effect of approvals and potential royalties or milestones.